All In Biotech

Drug Trial Radar · NCT05460429

Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus

An Open Clinical Trial to Evaluate Immunogenicity,Safety and Protective Effect of Live Attenuated Varicella Vaccine and a Clinical Trial on Antibody Level and Etiology of Varicella Zoster Virus in Zhejiang Province

Last checked: Nov 19, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

37,920

Planned (sponsor's estimate)

Start

Jul 30, 2022

Primary completion

Mar 15, 2023

Study completion May 15, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity and safety of a single dose of varicella vaccine in healthy children aged 1-6 years with different varicella immunization histories, to evaluate the antibody level of varicella-zoster virus in healthy people aged 0-59 years in Zhejiang Province.

Conditions

  • Varicella

Interventions

  • Live attenuated varicella vaccineBiological

    The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GMT of varicella antibody in children aged 1-6 yearsTime frame: 30 days after vaccination
  2. GMT of varicella antibody in healthy people aged 0-59 yearsTime frame: 30 days after vaccination

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Laian Center for Disease Control and Prevention

    Chuzhou, Anhui, China · Recruiting

  • Liandu District Center for Disease Control and Prevention

    Lishui, Zhejiang, China · Recruiting

  • Jiangshan Center for Disease Control and Prevention

    Quzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.